Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality

Blood

Volumn 125, Issue 22, 2015, Pages 3491-3500

  Schneidawind, Dominik ^a   Baker, Jeanette ^a   Pierini, Antonio ^a   Buechele, Corina ^b   Luong, Richard H ^c   Meyer, Everett H ^a   Negrin, Robert S ^a  

^a Division of Blood and Marrow Transplantation   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR HELIOS; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BIOLUMINESCENCE; BODY WEIGHT; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DIVISION; CELL EXPANSION; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PREVENTION; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; T CELL DEPLETION; TH1 CELL; TH2 CELL; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL PROTECTION; GRAFT VS HOST DISEASE; HELPER CELL; IMMUNOLOGY; MORTALITY; NATURAL KILLER CELL; PHYSIOLOGY; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOPROTECTION; FEMALE; GRAFT VS HOST DISEASE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84930960199     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-612762     Document Type: Article

References (95)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667-674.
2. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
3. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
4. Magenau J, Reddy P. Next generation treatment of acute graft-versus-host disease. Leukemia. 2014;28(12):2283-2291.
5. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J Exp Med. 1994;180(3): 1097-1106.
6. Schneidawind D, Pierini A, Negrin RS. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood. 2013;122(18):3116-3121.
7. Strober S, Modry DL, Hoppe RT, et al. Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. J Immunol. 1984;132(2):1013-1018.
8. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versushost disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant. 2003; 9(6):355-363.
9. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353(13):1321-1331.
10. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358(4):362-368.
11. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versushost disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5): 1099-1109.
12. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011; 365(14):1359-1360.
13. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012;12(5):1133-1145.
14. Schneidawind D, Pierini A, Alvarez M, et al. CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD251FoxP31 regulatory T cells. Blood. 2014;124(22):3320-3328.
15. Murphy GF, Bronstein BR, Knowles RW, Bhan AK. Ultrastructural documentation of M241 glycoprotein on dendritic and endothelial cells in normal human skin. Lab Invest. 1985;52(3):264-269.
16. Balk SP, Bleicher PA, Terhorst C. Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci USA. 1989;86(1):252-256.
17. Blumberg RS, Terhorst C, Bleicher P, et al. Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol. 1991;147(8):2518-2524.
18. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alphagalactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998;188(8):1521-1528.
19. Exley M, Garcia J, Wilson SB, et al. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 2000;100(1):37-47.
20. Borg NA, Wun KS, Kjer-Nielsen L, et al. CD1dlipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature. 2007;448(7149): 44-49.
21. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD251Foxp31 regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-462.
22. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
23. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101(2):640-648.
24. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008; 111(5):2919-2928.
25. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versushost disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122.
26. Hill JA, Feuerer M, Tash K, et al. Foxp3 transcription-factor-dependent and-independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27(5):786-800.
27. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymicderived from peripherally induced Foxp31 T regulatory cells. J Immunol. 2010;184(7): 3433-3441.
28. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010;116(25):5738-5747.
29. van der Merwe M, Abdelsamed HA, Seth A, Ong T, Vogel P, Pillai AB. Recipient myeloid-derived immunomodulatory cells induce PD-1 liganddependent donor CD4+Foxp31 regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation. J Immunol. 2013;191(11): 5764-5776.
30. Hongo D, Tang X, Baker J, Engleman EG, Strober S. Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant. 2014; 14(11):2467-2477.
31. Wilson MT, Johansson C, Olivares-Villagómez D, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA. 2003;100(19):10913-10918.
32. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101-117.
33. Chaidos A, Patterson S, Szydlo R, et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(21):5030-5036.
34. Rubio MT, Moreira-Teixeira L, Bachy E, et al. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood. 2012;120(10): 2144-2154.
35. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348-2357.
36. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987;166(5):1229-1244.
37. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood. 1994;84(10): 3540-3549.
38. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL. Polarized type 2 alloreactive CD4+ and CD81 donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155(2):585-593.
39. Tawara I, Maeda Y, Sun Y, et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol. 2008;36(8):988-996.
40. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101-3112.
41. Yao Z, Liu Y, Jones J, Strober S. Differences in Bcl-2 expression by T-cell subsets alter their balance after in vivo irradiation to favor CD4+Bcl-2hi NKT cells. Eur J Immunol. 2009; 39(3):763-775.
42. Seino K, Harada M, Taniguchi M. NKT cells are relatively resistant to apoptosis. Trends Immunol. 2004;25(5):219-221.
43. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649-2656.
44. Pierini A, Colonna L, Alvarez M, et al. Donor requirements for CD4+ CD251 FoxP31 regulatory T cells capable of suppressing CD4+ and CD81 conventional T cell proliferation and graft versus host disease. Blood. 2013;122(21): 4484.
45. Leveson-Gower DB, Olson JA, Sega EI. et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood. 2011;117(11): 3220-3229.
46. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol. 2007;7(7): 505-518.
47. Raberger J, Schebesta A, Sakaguchi S, et al. The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci USA. 2008;105(46): 17919-17924.
48. Gallatin WM, Weissman IL, Butcher EC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983;304(5921): 30-34.
49. Siegelman MH, van de Rijn M, Weissman IL. Mouse lymph node homing receptor cDNA clone encodes a glycoprotein revealing tandem interaction domains. Science. 1989;243(4895): 1165-1172.
50. Lasky LA, Singer MS, Dowbenko D, et al. An endothelial ligand for L-selectin is a novel mucinlike molecule. Cell. 1992;69(6):927-938.
51. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature. 1993; 363(6428):461-464.
52. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L1 subpopulation of CD4+CD251 regulatory T cells protects from lethal acute GVHD. Blood. 2005;105(5):2220-2226.
53. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006; 43(2 suppl 1):S54-S62.
54. Lalor PF, Shields P, Grant A, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol. 2002;80(1):52-64.
55. van der Vliet HJ, Nishi N, Koezuka Y, et al. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods. 2001;247(1-2):61-72.
56. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc. 2008;3(1): 70-78.
57. Exley MA, Wilson B, Balk SP. Isolation and functional use of human NKT cells. Curr Protoc Immunol. 2010;Chapter 14:Unit 14.11.
58. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
59. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. Blood. 2010;115(16): 3206-3214.
60. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014; 123(13):2017-2025.
61. Bader P, Kreyenberg H, Henze GH, et al; ALLREZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALLREZ BFM Study Group. J Clin Oncol. 2009;27(3): 377-384.
62. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189(6):3221-3230.
63. Faham M, Zheng J, Moorhead M, et al. Deepsequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180.
64. Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540-4548.
65. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Lower risk of serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014;123(23):3655-3663.
66. Carlson CS, Emerson RO, Sherwood AM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680.
67. Borowitz MJ, Wood BL, Devidas M, et al. Improved post-induction chemotherapy does not abrogate prognostic significance of minimal residual disease (MRD) for children and young adults with high risk acute lymphoblastic leukemia (ALL). A report from Children's Oncology Group (COG) Study AALL0232 [abstract]. Blood. 2011; 118(21). Abstract 1440.
68. Dworzak MN, Fröschl G, Printz D, et al; Austrian Berlin-Frankfurt-Munster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6): 1952-1958.
69. Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572.
70. Aalen OO, Johansen S. An empirical transition matrix for nonhomogeneous Markov chains based on censored observations. Scand J Stat. 1978; 5(3):141-150.
71. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913-3915.
72. Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial [published online ahead of print February 4, 2014]. Blood.
73. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340-347.
74. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant. 2003;32(6):543-548.
75. Eapen M, Raetz E, Zhang MJ, et al; Children's Oncology Group; Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006; 107(12):4961-4967.
76. Oliansky DM, Camitta B, Gaynon P, et al; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012; 18(4):505-522.
77. Oliansky DM, Camitta B, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012; 18(7):979-981.
78. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012;18(1):16-17.
79. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012;18(1):18-36.e6.
80. Socié G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348-357.
81. Leung W, Ahn H, Rose SR, et al. A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2007;86(4): 215-224.
82. Krull KR, Zhang N, Santucci A, et al. Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. Blood. 2013;122(4): 550-553.
83. Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood. 2009;114(7):1429-1436.
84. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma: a Children's Oncology Group study [published correction appears in J Clin Oncol. 2008;26(28):4697]. J Clin Oncol. 2008;26(24): 3971-3978.
85. Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013; 31(21):2736-2742.
86. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.
87. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001; 97(6):1572-1577.
88. Passweg JR, Tiberghien P, Cahn JY, et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21(2):153-158.
89. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002;16(11): 2228-2237.
90. Dini G, Zecca M, Balduzzi A, et al; Associazione Italiana Ematologia ed Oncologia Pediatrica-Hematopoietic Stem Cell Transplantation (AIEOP-HSCT) Group. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood. 2011; 118(25):6683-6690.
91. Davies SM, Wang D, Wang T, et al. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009;15(3): 360-366.
92. Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014;164(3):396-408.
93. Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplant. 2008;42(3): 187-196.
94. Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015; 33(11):1275-1284.
95. Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014; 20(9):1307-1313.